Public Health Trace

Get Alerts

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters

Drug Recall Ongoing Historical recordClass II

Vitamin B12 Cyanocobalamin 5000 mcg Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Vitamin B12 (3000 mcg/ml & 5000 mcg/ml) Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Vitamin A/D3/E Olive Oil Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Vitamin 15 (HEMO15) Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Tripelennamine 20 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Trimix, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Testosterone Cypionate (100 mg/ml & 200 mg/ml) Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Tacrolimus (0.02% and 0.03%) drops, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Stanozolol (50 mg/ml and 100 mg/ml) Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Sodium Tetradecyl Sulfate (0.125%, 1%, 2.5%, 3%, and 4%) Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Sodium Salicylate 40% Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Sodium Iodide 20% Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Sermorelin/GHRP 3 mg/3 mg vial, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Quadmix, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Progesterone EO 100 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Progesterone 100 mg/ml in Olive Oil Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Praziquantel 56.8mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Potassium Phosphate Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Phenylephrine 1 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Phenylbutazone 200 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Data last updated: October 3, 2026 ET

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.